Intramuscular interferon-beta-1a: in patients at high risk of developing clinically definite multiple sclerosis - PubMed

Review

Intramuscular interferon-beta-1a: in patients at high risk of developing clinically definite multiple sclerosis

M Asif A Siddiqui et al. CNS Drugs. 2005.

Abstract

Intramuscular interferon-beta-1a, a recombinant interferon-beta approved in the US for the treatment of relapsing forms of multiple sclerosis (MS), has also been evaluated in the treatment of patients with a first clinical demyelinating episode and brain lesions consistent with MS confirmed by magnetic resonance imaging (MRI). In a randomised, double-blind trial, patients at high risk of developing clinically definite MS who received intramuscular interferon-beta-1a 30 microg once weekly had a 44% reduction in the cumulative probability of developing MS, compared with placebo recipients (rate ratio 0.56; p = 0.002), over a 3-year period after a first, MRI-confirmed demyelinating event. These results were supported by MRI findings that showed significantly smaller increases in the volume of brain lesions and the number of new/enlarging and gadolinium-enhancing lesions in interferon-beta-1a recipients than in those receiving placebo. A nonblind extension of this trial demonstrated that early treatment with interferon-beta-1a significantly reduced the probability of developing MS by 35% (p = 0.03), compared with delayed treatment, over a 5-year period. Intramuscular interferon-beta-1a was generally well tolerated; however, influenza-like syndrome was documented in >50% of patients at high risk of developing clinically definite MS who received the drug.

Similar articles

• Intramuscular interferon beta-1a therapy initiated during a first demyelinating event in multiple sclerosis. CHAMPS Study Group.

  Jacobs LD, Beck RW, Simon JH, Kinkel RP, Brownscheidle CM, Murray TJ, Simonian NA, Slasor PJ, Sandrock AW. Jacobs LD, et al. N Engl J Med. 2000 Sep 28;343(13):898-904. doi: 10.1056/NEJM200009283431301. N Engl J Med. 2000. PMID: 11006365 Clinical Trial.

• Interferon beta-1a for optic neuritis patients at high risk for multiple sclerosis.

  CHAMPS Study Group. CHAMPS Study Group. Am J Ophthalmol. 2001 Oct;132(4):463-71. doi: 10.1016/s0002-9394(01)01209-0. Am J Ophthalmol. 2001. PMID: 11589865 Clinical Trial.

• Shifting the paradigm toward earlier treatment of multiple sclerosis with interferon beta.

  Comi G. Comi G. Clin Ther. 2009 Jun;31(6):1142-57. doi: 10.1016/j.clinthera.2009.06.007. Clin Ther. 2009. PMID: 19695384 Review.

• Clinical efficacy, effects on MRI and tolerability of weekly intramuscular interferon-beta-1a in patients with MS and CIS.

  Zivadinov R, Munschauer FE, Ramanathan M, Benedict RH, Weinstock-Guttman B. Zivadinov R, et al. Drugs Today (Barc). 2008 Aug;44(8):601-13. doi: 10.1358/dot.2008.44.8.1242250. Drugs Today (Barc). 2008. PMID: 18846271 Review.

Cited by

• Interferon-beta treatment for multiple sclerosis.

  Bermel RA, Rudick RA. Bermel RA, et al. Neurotherapeutics. 2007 Oct;4(4):633-46. doi: 10.1016/j.nurt.2007.07.001. Neurotherapeutics. 2007. PMID: 17920544 Free PMC article. Review.

References

Publication types

MeSH terms

Substances

LinkOut - more resources

• Full Text Sources

  • Ovid Technologies, Inc.
  • Springer

• Medical

  • MedlinePlus Health Information